Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer

Hikmat A. Al-Ahmadie; Gopa Iyer; Byron H. Lee; Sasinya N. Scott; Rohit Mehra; Aditya Bagrodia; Emmet J. Jordan; Sizhi Paul Gao; Ricardo Ramirez; Eugene K. Cha; Neil B. Desai; Emily C. Zabor; Irina Ostrovnaya; Anuradha Gopalan; Ying Bei Chen; Samson W. Fine; Satish K. Tickoo; Anupama Gandhi; Joseph Hreiki; Agns Viale; Maria E. Arcila; Guido Dalbagni; Jonathan E. Rosenberg; Bernard H. Bochner; Dean F. Bajorin; Michael F. Berger; Victor E. Reuter; Barry S. Taylor; David B. Solit

doi:10.1038/ng.3503

Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer

Hikmat A. Al-Ahmadie, Gopa Iyer, Byron H. Lee, Sasinya N. Scott, Rohit Mehra, Aditya Bagrodia, Emmet J. Jordan, Sizhi Paul Gao, Ricardo Ramirez, Eugene K. Cha, Neil B. Desai, Emily C. Zabor, Irina Ostrovnaya, Anuradha Gopalan, Ying Bei Chen, Samson W. Fine, Satish K. Tickoo, Anupama Gandhi, Joseph Hreiki, Agns VialeMaria E. Arcila, Guido Dalbagni, Jonathan E. Rosenberg, Bernard H. Bochner, Dean F. Bajorin, Michael F. Berger, Victor E. Reuter, Barry S. Taylor, David B. Solit

Research output: Contribution to journal › Article › peer-review

110 Scopus citations

Abstract

Plasmacytoid bladder cancer is an aggressive histologic variant with a high risk of disease-specific mortality. Using whole-exome and targeted sequencing, we find that truncating somatic alterations in the CDH1 gene occur in 84% of plasmacytoid carcinomas and are specific to this histologic variant. Consistent with the aggressive clinical behavior of plasmacytoid carcinomas, which frequently recur locally, CRISPR/Cas9-mediated knockout of CDH1 in bladder cancer cells enhanced cell migration.

Original language	English (US)
Pages (from-to)	356-358
Number of pages	3
Journal	Nature genetics
Volume	48
Issue number	4
DOIs	https://doi.org/10.1038/ng.3503
State	Published - Mar 29 2016

ASJC Scopus subject areas

Genetics

Access to Document

10.1038/ng.3503

Cite this

Al-Ahmadie, H. A., Iyer, G., Lee, B. H., Scott, S. N., Mehra, R., Bagrodia, A., Jordan, E. J., Gao, S. P., Ramirez, R., Cha, E. K., Desai, N. B., Zabor, E. C., Ostrovnaya, I., Gopalan, A., Chen, Y. B., Fine, S. W., Tickoo, S. K., Gandhi, A., Hreiki, J., ... Solit, D. B. (2016). Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nature genetics, 48(4), 356-358. https://doi.org/10.1038/ng.3503

Al-Ahmadie, HA, Iyer, G, Lee, BH, Scott, SN, Mehra, R, Bagrodia, A, Jordan, EJ, Gao, SP, Ramirez, R, Cha, EK, Desai, NB, Zabor, EC, Ostrovnaya, I, Gopalan, A, Chen, YB, Fine, SW, Tickoo, SK, Gandhi, A, Hreiki, J, Viale, A, Arcila, ME, Dalbagni, G, Rosenberg, JE, Bochner, BH, Bajorin, DF, Berger, MF, Reuter, VE, Taylor, BS & Solit, DB 2016, 'Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer', Nature genetics, vol. 48, no. 4, pp. 356-358. https://doi.org/10.1038/ng.3503

@article{270d9bda781143c48c83ae06a6fbdee0,

title = "Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer",

abstract = "Plasmacytoid bladder cancer is an aggressive histologic variant with a high risk of disease-specific mortality. Using whole-exome and targeted sequencing, we find that truncating somatic alterations in the CDH1 gene occur in 84% of plasmacytoid carcinomas and are specific to this histologic variant. Consistent with the aggressive clinical behavior of plasmacytoid carcinomas, which frequently recur locally, CRISPR/Cas9-mediated knockout of CDH1 in bladder cancer cells enhanced cell migration.",

author = "Al-Ahmadie, {Hikmat A.} and Gopa Iyer and Lee, {Byron H.} and Scott, {Sasinya N.} and Rohit Mehra and Aditya Bagrodia and Jordan, {Emmet J.} and Gao, {Sizhi Paul} and Ricardo Ramirez and Cha, {Eugene K.} and Desai, {Neil B.} and Zabor, {Emily C.} and Irina Ostrovnaya and Anuradha Gopalan and Chen, {Ying Bei} and Fine, {Samson W.} and Tickoo, {Satish K.} and Anupama Gandhi and Joseph Hreiki and Agns Viale and Arcila, {Maria E.} and Guido Dalbagni and Rosenberg, {Jonathan E.} and Bochner, {Bernard H.} and Bajorin, {Dean F.} and Berger, {Michael F.} and Reuter, {Victor E.} and Taylor, {Barry S.} and Solit, {David B.}",

note = "Publisher Copyright: {\textcopyright} 2016 Nature America, Inc.",

year = "2016",

month = mar,

day = "29",

doi = "10.1038/ng.3503",

language = "English (US)",

volume = "48",

pages = "356--358",

journal = "Nature Genetics",

issn = "1061-4036",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer

AU - Al-Ahmadie, Hikmat A.

AU - Iyer, Gopa

AU - Lee, Byron H.

AU - Scott, Sasinya N.

AU - Mehra, Rohit

AU - Bagrodia, Aditya

AU - Jordan, Emmet J.

AU - Gao, Sizhi Paul

AU - Ramirez, Ricardo

AU - Cha, Eugene K.

AU - Desai, Neil B.

AU - Zabor, Emily C.

AU - Ostrovnaya, Irina

AU - Gopalan, Anuradha

AU - Chen, Ying Bei

AU - Fine, Samson W.

AU - Tickoo, Satish K.

AU - Gandhi, Anupama

AU - Hreiki, Joseph

AU - Viale, Agns

AU - Arcila, Maria E.

AU - Dalbagni, Guido

AU - Rosenberg, Jonathan E.

AU - Bochner, Bernard H.

AU - Bajorin, Dean F.

AU - Berger, Michael F.

AU - Reuter, Victor E.

AU - Taylor, Barry S.

AU - Solit, David B.

PY - 2016/3/29

Y1 - 2016/3/29

N2 - Plasmacytoid bladder cancer is an aggressive histologic variant with a high risk of disease-specific mortality. Using whole-exome and targeted sequencing, we find that truncating somatic alterations in the CDH1 gene occur in 84% of plasmacytoid carcinomas and are specific to this histologic variant. Consistent with the aggressive clinical behavior of plasmacytoid carcinomas, which frequently recur locally, CRISPR/Cas9-mediated knockout of CDH1 in bladder cancer cells enhanced cell migration.

AB - Plasmacytoid bladder cancer is an aggressive histologic variant with a high risk of disease-specific mortality. Using whole-exome and targeted sequencing, we find that truncating somatic alterations in the CDH1 gene occur in 84% of plasmacytoid carcinomas and are specific to this histologic variant. Consistent with the aggressive clinical behavior of plasmacytoid carcinomas, which frequently recur locally, CRISPR/Cas9-mediated knockout of CDH1 in bladder cancer cells enhanced cell migration.

UR - http://www.scopus.com/inward/record.url?scp=84959128389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959128389&partnerID=8YFLogxK

U2 - 10.1038/ng.3503

DO - 10.1038/ng.3503

M3 - Article

C2 - 26901067

AN - SCOPUS:84959128389

SN - 1061-4036

VL - 48

SP - 356

EP - 358

JO - Nature Genetics

JF - Nature Genetics

IS - 4

ER -

Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this